NCT02172144已完成1 期
A Double-blind, Randomised, Placebo Controlled, Six-way Crossover Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Influence of Via Respimat® Inhaled BI 1744 CL (Single Doses of 10 μg, 20 μg, 30 μg and 50 μg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Change from baseline in the mean time-matched QTcI (QT interval, individually corrected according to the factor estimated from each subject)
研究概览
简要总结
Study to investigate the effect of BI 1744 CL on the QT/QTc interval of the ECG (electrocardiogram) in comparison to placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All participants in the study will be healthy males or females, ranging from 21 to 50 years of age, with a body mass index (BMI) be within 18.5 to 29.9 kg/m2 (BMI calculation: weight in kilograms divided by the square of height in meters). In accordance with Good Clinical Practice and the local legislation all volunteers will have given their written informed consent prior to admission to the study
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, clinically relevant electrolyte disturbances
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or clinically relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
- •Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
- •Participation in another trial with an investigational drug (within two months prior to administration or during the trial)
- •Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (> 60 g/day for males and > 20 g/day for females)
- •Drug abuse
- •Blood donation (> 100 mL within four weeks prior to administration or during the trial)
- •Any laboratory value outside the reference range if indicative of underlying disease or poor health
- •Excessive physical activities within the last week before the trial or during the trial
- •Hypersensitivity to treatment medication, moxifloxacin and/or related drugs of these classes
- •Previous tendon disease related to quinolone treatment
- •Congenital or documented acquired QT- prolongation, previous history of symptomatic arrhythmias
- •Pulse rate at screening of > 80 bpm or < 45 bpm
- •Any screening ECG value outside of the reference range of clinical relevance including, but not limited to PR (Pulse rate) interval > 220 ms, QRS interval > 115 ms, QTcB > 450 ms, or QT (uncorrected) > 470 ms
- •For Female Subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception (adequate contraception e.g. sterilisation, intrauterine-pressure, oral contraceptives)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
BI 1744 CL
Experimental
干预措施: BI 1744 CL solution for inhalation (Drug)
Placebo
Placebo Comparator
干预措施: Placebo matching BI 1744 CL (Drug)
Moxifloxacin (Avalox®)
Active Comparator
干预措施: Moxifloxacin (Avalox®) (Drug)
结局指标
主要结局
Change from baseline in the mean time-matched QTcI (QT interval, individually corrected according to the factor estimated from each subject)
时间窗: Baseline (day -1) and 20 to 120 min. after drug administration
次要结局
- Change of the QTcI at different point(Baseline (day -1) and 10 min. to 8 hours after drug administration)
- The mean of the QTcI values of all ECGs for Moxifloxacin and Placebo(1 to 4 hours after drug administration)
研究者
相似试验
已完成
1 期
Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female VolunteersHealthyNCT02256735Boehringer Ingelheim39
已完成
1 期
A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult ParticipantsHealthyNCT03696459Janssen Research & Development, LLC52
已完成
1 期
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineSchizophreniaSchizoaffective DisorderNCT00791622Johnson & Johnson Pharmaceutical Research & Development, L.L.C.110
已完成
1 期
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy SubjectsHealthy SubjectsNCT05293171BioLineRx, Ltd.38
已完成
1 期
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsAlzheimer DiseaseNCT00979316Bristol-Myers Squibb62